Repligen (RGEN) and 908 Devices (MASS) announced that Repligen has purchased 908 Devices’ desktop portfolio of four devices for bioprocessing process analytical technology applications. 908 Devices remains focused on the growth of its newly expanded handheld device portfolio for vital health and safety applications. The purchase consideration is a payment of $70M in cash.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Repligen Delays 2024 Yearly Report Filing
- Buy Recommendation for Repligen Driven by Strong Performance and Positive Growth Outlook
- Repligen’s Earnings Call: Growth Amid Challenges
- Repligen: Strong Market Position and Growth Potential Justify Buy Rating
- Repligen price target raised to $170 from $165 at Canaccord
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue